Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359632 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00359632 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 34 participants.
The verdict
NCT00359632, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual disturbance or eye disorders.
Interventions
- DRUG Matched control
- DRUG Zyvox - linezolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359632
The ClinicalTrials.gov registry entry for NCT00359632 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matched control is the first listed.
NCT00359632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359632 about?
NCT00359632 is a clinical study titled "Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater". To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual disturbance or eye disorders.
What is the current status of trial NCT00359632?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2008-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00359632?
The interventions under investigation include: Matched control (DRUG), Zyvox - linezolid (DRUG).
Who is sponsoring clinical trial NCT00359632?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.